Mesothelin-Targeted CAR T Cells With or Without Pembrolizumab for Malignant Pleural Disease

Phase 2, open-label trial of IcasM28z in malignant pleural disease (MPD), mesothelioma, non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings and physical examination at 1 year and Clinical Benefit Rate at 12 weeks. Started May 2015; status: active, not recruiting.